Northstar Group Inc. Has $6.49 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Northstar Group Inc. lowered its position in Johnson & Johnson (NYSE:JNJ) by 1.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 40,053 shares of the company’s stock after selling 413 shares during the quarter. Johnson & Johnson accounts for about 1.1% of Northstar Group Inc.’s holdings, making the stock its 20th largest position. Northstar Group Inc.’s holdings in Johnson & Johnson were worth $6,491,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Putnam Investments LLC grew its holdings in Johnson & Johnson by 0.3% during the fourth quarter. Putnam Investments LLC now owns 624,978 shares of the company’s stock valued at $97,959,000 after purchasing an additional 2,128 shares during the period. Kestra Advisory Services LLC lifted its holdings in Johnson & Johnson by 3.9% during the fourth quarter. Kestra Advisory Services LLC now owns 328,605 shares of the company’s stock worth $51,505,000 after acquiring an additional 12,265 shares in the last quarter. Waverly Advisors LLC grew its position in shares of Johnson & Johnson by 45.9% in the 4th quarter. Waverly Advisors LLC now owns 77,334 shares of the company’s stock valued at $12,121,000 after purchasing an additional 24,318 shares during the period. Pinnacle Holdings LLC lifted its holdings in shares of Johnson & Johnson by 5.4% in the fourth quarter. Pinnacle Holdings LLC now owns 13,265 shares of the company’s stock valued at $2,079,000 after purchasing an additional 685 shares in the last quarter. Finally, Pathstone Holdings LLC bought a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $55,434,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Price Performance

Shares of NYSE JNJ traded up $0.69 during midday trading on Thursday, reaching $161.34. The company’s stock had a trading volume of 396,395 shares, compared to its average volume of 7,026,207. The company has a market cap of $388.29 billion, a P/E ratio of 10.02, a P/E/G ratio of 2.69 and a beta of 0.52. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. The business’s 50 day moving average price is $162.65 and its two-hundred day moving average price is $154.41.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. The business had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. Johnson & Johnson’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.80 earnings per share. On average, analysts forecast that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were given a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $4.96 annualized dividend and a dividend yield of 3.07%. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Insider Activity at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is currently owned by insiders.

Analysts Set New Price Targets

JNJ has been the subject of several recent research reports. Sanford C. Bernstein increased their target price on shares of Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. TD Cowen decreased their price objective on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a report on Thursday, July 18th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Monday, September 30th. Royal Bank of Canada raised their target price on shares of Johnson & Johnson from $175.00 to $178.00 and gave the company an “outperform” rating in a research note on Tuesday. Finally, Morgan Stanley increased their price target on shares of Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a research note on Thursday, July 18th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $173.43.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.